Retin Cases Brief Rep. 2025 Apr 16. doi: 10.1097/ICB.0000000000001765. Online ahead of print.
ABSTRACT
PURPOSE: Evaluate the safety and efficacy of membrane rich in growth factors (mPRGF) and its effects on retinal vasculature and anatomy in refractory and poor-prognosis macular holes.
METHODS: Retrospective, interventional, longitudinal, case series and single-center study conducted at Dr. Elías Santana Hospital, Dominican Republic. Patients with macular hole larger than 400 microns, refractory or with poor prognosis were treated with posterior pars plana vitrectomy (PPV) plus adjuvant therapy mPRGF. A total of seven eyes were included: refractory MH (n=6) and traumatic MH (n=1). The anatomical closure was evaluated by optical coherence tomography (OCT) and foveal avascular zone (FAZ), and foveal density (FD) was measured with optical coherence tomography angiography (OCT-A) pre- and post-surgery. Also, the corrected visual acuity (CVA) was compared pre- and post-intervention.
RESULTS: A total of seven eyes were intervened with a surgical-anatomic closure rate was 85.7%. The average CVA resulted in an improvement of over six lines in Snellen notation which was statistically significant (p=0.036). FAZ and FD showed a decrease (p=0.002) and increase (p=0.043), respectively after surgery.
CONCLUSIONS: In conclusion, this clinical research provides compelling evidence supporting the efficacy and safety of mPRGF in achieving the anatomical closure of refractory or traumatic macular holes larger than 400 microns. Notably, mPRGF treatment demonstrated significant improvements in patients’ visual acuity and contributed to the restoration of normal retinal vasculature. These exciting results pave the way for the potential utilization of mPRGF as a reproducible and cost-effective adjuvant therapy in the surgical management of macular holes.
PMID:40258274 | DOI:10.1097/ICB.0000000000001765
